Compare VanEck Rare Earth/Strategic Metals (REMX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Sanofi SA — how do they compare? VanEck Rare Earth/Strategic Metals trades at $71.1, while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA pays a 5.53% dividend while VanEck Rare Earth/Strategic Metals pays none, and VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| REMX | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $52.34 |
52-Week Low | $49.22 | $41.33 |
Market Cap | — | $104.85B |
Enterprise Value | — | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $69.85, down 3.88% amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals against zero bullish, though oscillators show some buying opportunity with RSI readings in oversold territory. Recent news highlights ongoing geopolitical tensions around rare earth supply chains, with China's export controls and US efforts to secure critical minerals driving volatility in the sector.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China concentration risk. While strategic metals demand remains strong for technology and defense applications, REMX is best suited as a satellite holding for aggressive portfolios due to its specialized nature and geopolitical sensitivities.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
